MCID: DRG024
MIFTS: 40

Drug Allergy

Categories: Immune diseases

Aliases & Classifications for Drug Allergy

MalaCards integrated aliases for Drug Allergy:

Name: Drug Allergy 12 15
Drug Allergies 63
Allergy Drug 55

Classifications:



External Ids:

Disease Ontology 12 DOID:0060500

Summaries for Drug Allergy

Disease Ontology : 12 A hypersensitivity reaction type I disease triggered by a drug.

MalaCards based summary : Drug Allergy, also known as drug allergies, is related to allergic hypersensitivity disease and asthma. An important gene associated with Drug Allergy is IL4R (Interleukin 4 Receptor), and among its related pathways/superpathways are Allograft rejection and IL4-mediated signaling events. The drugs Tranexamic Acid and Alendronate have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and liver, and related phenotype is digestive/alimentary.

Wikipedia : 76 A drug allergy is an allergy to a drug, most commonly a medication, and is a form of adverse drug... more...

Related Diseases for Drug Allergy

Diseases related to Drug Allergy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Related Disease Score Top Affiliating Genes
1 allergic hypersensitivity disease 30.1 IL4R IL5 MS4A2
2 asthma 29.7 CYP3A4 IL4R IL5 INS MS4A2
3 food allergy 29.7 ALB IL5 MS4A2
4 beta-lactam allergy 11.3
5 aspirin allergy 11.0
6 carbamazepine allergy 11.0
7 abacavir allergy 11.0
8 isoniazide allergy 11.0
9 lidocaine allergy 11.0
10 mepivacaine allergy 11.0
11 phenobarbital allergy 11.0
12 phenytoin allergy 11.0
13 ranitidine allergy 11.0
14 corticosteroid allergy 11.0
15 sulfonamide allergy 11.0
16 sulfamethoxazole allergy 11.0
17 suprofen allergy 11.0
18 thiopental allergy 11.0
19 d-mannitol allergy 11.0
20 cephalosporin allergy 11.0
21 amodiaquine allergy 11.0
22 chlorhexidine allergy 11.0
23 cyclophosphamide allergy 11.0
24 succinylcholine allergy 11.0
25 trimethoprim allergy 11.0
26 diclofenac allergy 11.0
27 carbapenem allergy 11.0
28 rocuronium allergy 11.0
29 sulfasalazine allergy 11.0
30 tubocurarine allergy 11.0
31 quinidine allergy 11.0
32 melphalan allergy 11.0
33 co-trimoxazole allergy 11.0
34 sodium aurothiomalate allergy 11.0
35 disodium cromoglycate allergy 11.0
36 phthalyl group allergy 11.0
37 alcuronium bromide allergy 11.0
38 gallamine allergy 11.0
39 patent blue v allergy 11.0
40 oxirane allergy 11.0
41 sinusitis 10.2 IL4R IL5
42 pollen allergy 10.2 IL4R IL5
43 esophageal candidiasis 10.1 ATP12A CYP3A4
44 duodenitis 10.1 ATP12A INS
45 neurodermatitis 10.1 INS MS4A2
46 eosinophilic gastritis 10.1 ATP12A IL5
47 functional gastric disease 10.1 ATP12A INS
48 conjunctival disease 10.1 IL5 MS4A2
49 hypertensive nephropathy 10.1 ALB CYP3A4
50 severe nonproliferative diabetic retinopathy 10.1 ALB INS

Graphical network of the top 20 diseases related to Drug Allergy:



Diseases related to Drug Allergy

Symptoms & Phenotypes for Drug Allergy

MGI Mouse Phenotypes related to Drug Allergy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.02 ALB ATP12A IL4R IL5 INS

Drugs & Therapeutics for Drug Allergy

Drugs for Drug Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 279)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tranexamic Acid Approved Phase 4 1197-18-8 5526
2
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
3
Aspirin Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-78-2 2244
4
Epinastine Approved, Investigational Phase 4 80012-43-7 3241
5
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 51-45-6, 75614-87-8 774
6
Omalizumab Approved, Investigational Phase 4,Phase 1 242138-07-4
7
Azelastine Approved Phase 4,Phase 3 58581-89-8 2267
8
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
9
Ofloxacin Approved Phase 4 82419-36-1 4583
10
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
11
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
12
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
13
Methotrexate Approved Phase 4,Phase 3 59-05-2, 1959-05-2 126941
14
Infliximab Approved Phase 4,Phase 1,Phase 2 170277-31-3
15
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
16
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
17
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
18
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
19
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
20
leucovorin Approved Phase 4,Phase 3 58-05-9 6006 143
21
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Not Applicable 738-70-5 5578
22
Sulfamethoxazole Approved Phase 4,Phase 3,Not Applicable 723-46-6 5329
23
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
24
Metronidazole Approved Phase 4 443-48-1 4173
25
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
26
Clarithromycin Approved Phase 4 81103-11-9 84029
27
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
28
Dapsone Approved, Investigational Phase 4 80-08-0 2955
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 59-30-3 6037
31
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
32
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 77-92-9 311
33
BCG vaccine Investigational Phase 4
34 Antifibrinolytic Agents Phase 4
35 Coagulants Phase 4
36 Hemostatics Phase 4
37 Calcium, Dietary Phase 4,Phase 3,Not Applicable
38 Bone Density Conservation Agents Phase 4
39 Calciferol Phase 4
40 Vitamins Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Diphosphonates Phase 4
42 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Not Applicable
43 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Not Applicable
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Ophthalmic Solutions Phase 4,Not Applicable
49 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
50 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 174)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section Unknown status NCT02279186 Phase 4 Tranexamic Acid
2 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
3 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday
4 Efficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment Completed NCT02982603 Phase 4 Qinggongshoutao Bolus;Ginkgo Biloba Extract 761;Placebos
5 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
6 Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) Completed NCT00367016 Phase 4 Xolair (Omalizumab);Placebo
7 Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR Completed NCT01880840 Phase 4 205.5 mcg of azelastine hydrochloride;137 mcg of azelastine hydrochloride
8 Grass Pollen Subcutaneous Immunotherapy in Elderly Patients Completed NCT02440243 Phase 4 Purethal;Purethal -placebo
9 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. Completed NCT01694108 Phase 4
10 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
11 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
12 Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori Completed NCT03087162 Phase 4 Dexlansoprazole 60 mg once daily
13 Centocor Microarray Study of Patients Completed NCT00462072 Phase 4 Infliximab
14 Effect of Dexmedetomidine on Emergence Agitation in Children With or Without Tube Insertion Under General Anesthesia Completed NCT01535287 Phase 4 Dexmedetomidine
15 The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases Completed NCT01867281 Phase 4 aspirin
16 Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail Completed NCT02961998 Phase 4 Celecoxib;Sorafenib
17 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
18 Basophil Activation Test (BAT) Sensitivity in Child Food Allergy Recruiting NCT01966640 Phase 4
19 Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy Recruiting NCT03708848 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Clarithromycin;Metronidazole;Levofloxacin;Tetracycline
20 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Recruiting NCT02550080 Phase 4 Dapsone
21 G-CSF in the Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
22 Co-trimoxazole as Maintenance Therapy for Meliodosis Active, not recruiting NCT01420341 Phase 4 Co-trimoxazole 12;Co-trimoxazole 20
23 Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer Unknown status NCT02794493 Phase 3 Traditional Chinese Medicine Formula LC09
24 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer Unknown status NCT00559858 Phase 3
25 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis Completed NCT00432757 Phase 3 Ketotifen with a Contact Lens (generic name not yet established)
26 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis Completed NCT00445874 Phase 3 Ketotifen with a Contact Lens (no generic name)
27 Phase III Cat-PAD Follow-on Study Completed NCT02040844 Phase 3 Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762];Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762];Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]
28 Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery Completed NCT01294163 Phase 3 Xenon;Sevoflurane;Propofol
29 A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy Completed NCT00053638 Phase 3 efavirenz;tenofovir;abacavir/lamivudine
30 A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis Completed NCT01018862 Phase 3 Azelastine hydrochloride nasal spray 0.15%;Azelastine hydrochloride nasal spray 0.10%;Placebo
31 ICMR-Indiaclen Trial on Amoxycillin vs Cotrimoxazole for Non-Severe Pneumonia Completed NCT00396526 Phase 3 Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.
32 Indiaclen Short Course Amoxycillin Therapy for Pneumonia With Wheeze Completed NCT00407394 Phase 3 Amoxycillin
33 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies Completed NCT00712920 Phase 3 0.15% azelastine hydrochloride;0.1% azelastine hydrochloride;Placebo
34 A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies Completed NCT00720278 Phase 3 0.15% azelastine hydrochloride 1644 mcg daily;0.1% azelastine hydrochloride 1096 mcg daily;Placebo
35 SUBLIVAC FIX Birch Phase III Short-term Efficacy Completed NCT02231307 Phase 3 SUBLIVAC FIX Birch
36 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00824473 Phase 3 Placebo;0.15% azelastine hydrochloride
37 A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00719862 Phase 3 Placebo nasal spray;0.15% azelastine hydrochloride Nasal Spray
38 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00660829 Phase 3 Placebo;0.15% Azelastine Hydrochloride
39 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00660517 Phase 3 MP29-02;azelastine Hcl;fluticasone propionate;placebo
40 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00651118 Phase 3 Placebo;azelastine Hcl;azelastineHcl / fluticasone propionate;fluticasone propionate
41 A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00740792 Phase 3 azelastine HCl/fluticasone propionate;azelastine Hcl;fluticasone propionate;placebo
42 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed NCT00883168 Phase 3 Placebo;azelastineHcl;fluticasone propionate;azelastine Hcl/fluticasone propionate
43 Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis Completed NCT01731249 Phase 3
44 Avanz Phleum Pratense Maintenance Dose Completed NCT01438827 Phase 2, Phase 3 Avanz Phleum pratense;Placebo
45 Improving Safety by Basic Computerizing Outpatient Prescribing Completed NCT01091038 Phase 2, Phase 3
46 Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers Completed NCT00569777 Phase 3
47 Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers Completed NCT00889252 Phase 3
48 Natalizumab Re-Initiation of Dosing Completed NCT00306592 Phase 3
49 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) Completed NCT00642460 Phase 3 tocilizumab [RoActemra/Actemra];Placebo;Non-steroidal anti-inflammatory drugs (NSAIDs);methotrexate;corticosteroids
50 A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383) Completed NCT02550288 Phase 3 Ezetimibe 10 mg;Atorvastatin 10 mg;Placebo for Ezetimibe 10 mg tablet;Placebo for Atorvastatin 10 mg capsule

Search NIH Clinical Center for Drug Allergy

Genetic Tests for Drug Allergy

Anatomical Context for Drug Allergy

MalaCards organs/tissues related to Drug Allergy:

41
Testes, Skin, Liver, Kidney, Bone, Lung, T Cells

Publications for Drug Allergy

Articles related to Drug Allergy:

(show top 50) (show all 458)
# Title Authors Year
1
Asthma, Family History of Drug Allergy, and Age Predict Amoxicillin Allergy in Children. ( 29226807 )
2018
2
Drug allergy evaluation for betalactam hypersensitivity: Cross-reactivity with cephalosporines, carbapenems and negative predictive value. ( 28577519 )
2018
3
A survey of drug allergy training opportunities in the United States. ( 28958742 )
2018
4
What can we learn in drug allergy management from World Health Organization's international classifications? ( 29105793 )
2018
5
Fifteen-minute consultation: A child with a suspected drug allergy. ( 29122832 )
2018
6
Evaluation of 'Definite' Anaphylaxis Drug Allergy Alert Overrides in Inpatient and Outpatient Settings. ( 29124665 )
2018
7
The Role of the Clinical History in Drug Allergy Prediction. ( 29310757 )
2018
8
Multiple drug intolerance syndrome and multiple drug allergy syndrome: Epidemiology and associations with anxiety and depression. ( 29574787 )
2018
9
Identification and management of drug allergy. ( 29583170 )
2018
10
Dendrimeric Antigens for Drug Allergy Diagnosis: A New Approach for Basophil Activation Tests. ( 29695102 )
2018
11
Diagnosing and managing drug allergy. ( 29712672 )
2018
12
Sulfonamide Drug Allergy. ( 29876667 )
2018
13
Clarification of Drug Allergy Information Using a Standardized Drug Allergy Questionnaire and Interview. ( 30100688 )
2018
14
Improving drug allergy management in Australia: education, communication and accurate information. ( 30157407 )
2018
15
Clinical Decision Support Systems for Drug Allergy Checking: Systematic Review. ( 30194058 )
2018
16
TEMPORARY REMOVAL: Controversies in Drug Allergy: Beta-Lactam Hypersensitivity Testing. ( 30245291 )
2018
17
Drug allergy. ( 30275849 )
2018
18
Highlights and recent developments in food and drug allergy, and anaphylaxis in EAACI Journals (2017). ( 30276869 )
2018
19
Drug Allergy. ( 30308679 )
2018
20
Overview of Drug Allergy: From Immunogenetic Basis to Practice. ( 30387427 )
2018
21
New role for the modern allergist in drug allergy: Assess, diagnose, and de-label. ( 30389081 )
2018
22
"Drug Allergy in children and adults: is it the double X chromosome?" ( 30465863 )
2018
23
A cross-sectional observational study of high override rates of drug allergy alerts in inpatient and outpatient settings, and opportunities for improvement. ( 26993641 )
2017
24
Designing Predictive Models for Beta-Lactam Allergy Using the Drug Allergy and Hypersensitivity Database. ( 28739365 )
2017
25
Frequency and Risk Factors of Penicillin and Amoxicillin Allergy in Suspected Patients with Drug Allergy. ( 28112529 )
2017
26
Cross sectional questionnaire-based internet study: Self-perception and clinical course of drug allergy in Greece. ( 27302696 )
2017
27
Towards improved drug allergy alerts: Multidisciplinary expert recommendations. ( 27729200 )
2017
28
Cutaneous Manifestation of Drug Allergy and Hypersensitivity. ( 27886905 )
2017
29
Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. ( 28122115 )
2017
30
Anaphylaxis during general anaesthesia: experience from a drug allergy centre in the UK. ( 28164272 )
2017
31
The Importance of Prolonged Provocation in Drug Allergy - Results From a Danish Allergy Clinic. ( 28454683 )
2017
32
Drug Allergy: Phenotypes, Endotypes, and Biomarkers. ( 28483316 )
2017
33
Drug allergy/hypersensitivity in adults and children. ( 28598865 )
2017
34
Frequency of self-reported drug allergy: A systematic review and meta-analysis with meta-regression. ( 28779998 )
2017
35
Pattern of inpatient referrals to a drug allergy unit in Kuwait. ( 29249136 )
2017
36
Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review. ( 29293931 )
2017
37
Self-diagnosed drug allergies: the belief of patients. ( 28602024 )
2017
38
Rare drug allergies: Review on prevalence and test procedures. ( 30402614 )
2017
39
Prevalence of beta-lactam allergy: a retrospective chart review of drug allergy assessment in a predominantly pediatric population. ( 27956906 )
2016
40
Drug allergy: diagnosis and management of drug allergy in adults, children and young people; a look at NICE guidance. ( 26908940 )
2016
41
Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. ( 26416157 )
2016
42
Optimization of clinical decision support through minimization of excessive drug allergy alerts. ( 27045062 )
2016
43
Eosinophilic Drug Allergy. ( 26006718 )
2016
44
Multiple drug allergy: A case of anaphylaxis to levofloxacin but tolerance to ciprofloxacin. ( 27009438 )
2016
45
Reciprocal contribution of Th17 and regulatory T cells in severe drug allergy. ( 26596217 )
2016
46
Drug allergy passport and other documentation for patients with drug hypersensitivity - An ENDA/EAACI Drug Allergy Interest Group Position Paper. ( 27145347 )
2016
47
Provocation proven drug allergy in Thai children with adverse drug reactions. ( 26994627 )
2016
48
Rising drug allergy alert overrides in electronic health records: an observational retrospective study of a decade of experience. ( 26578227 )
2016
49
In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. ( 26991315 )
2016
50
Knowledge, attitudes, and practices survey of drug allergy among healthcare practitioners in central China: a multicenter study. ( 27141484 )
2016

Variations for Drug Allergy

Expression for Drug Allergy

Search GEO for disease gene expression data for Drug Allergy.

Pathways for Drug Allergy

GO Terms for Drug Allergy

Molecular functions related to Drug Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxygen binding GO:0019825 8.62 ALB CYP3A4

Sources for Drug Allergy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....